Zepbound for Sleep Apnea: The First OSA Medication

The first prescription medication ever approved for obstructive sleep apnea. SURMOUNT-OSA trial data, eligibility, CPAP considerations, and the insurance pathway.

In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication ever approved to treat obstructive sleep apnea — specifically, moderate-to-severe OSA in adults with obesity. For decades, sleep apnea meant one thing: CPAP. Now there's a second option, and for many patients, a coverage pathway that weight-loss indications alone don't open.

This guide covers the SURMOUNT-OSA trial evidence, who qualifies, what it means for CPAP users, and the insurance angle that's quietly becoming the most important part of the story.

The SURMOUNT-OSA Trial

The FDA approval was based on two Phase 3, 52-week, randomized, double-blind, placebo-controlled studies enrolling 469 adults with obesity (BMI ≥ 30) and moderate-to-severe OSA (apnea-hypopnea index ≥ 15). Participants received either tirzepatide 10 mg or 15 mg, or placebo, once weekly.

• Study 1 (no CPAP): Tirzepatide reduced AHI by about 25 events per hour vs. 5 events for placebo. 42.2% achieved OSA remission or mild nonsymptomatic OSA (vs. 15.9% placebo).
• Study 2 (with CPAP): Tirzepatide reduced AHI by about 29 events per hour vs. 5 events for placebo. 50.2% achieved remission or mild OSA (vs. 14.3% placebo).
• Weight loss: 18% (no-CPAP group) and 20% (CPAP group) average body weight reduction at 52 weeks.
• Secondary benefits: Significant reductions in systolic blood pressure and high-sensitivity C-reactive protein (a marker of systemic inflammation).

Nearly half of trial participants had improvements significant enough that they no longer met the clinical threshold for symptomatic OSA after one year of treatment.

How It Actually Works

Zepbound doesn't act on the airway directly. The AHI improvement is a downstream effect of weight loss. OSA in people with obesity is driven largely by fat deposition in the upper airway (narrowing the lumen) and visceral fat in the chest (reducing lung capacity). Losing 18–20% of body weight reverses much of that mechanical obstruction.

Does This Replace CPAP?

No — and the FDA approval doesn't frame it that way. Zepbound is indicated as an option for patients who are unable or unwilling to use PAP therapy, or as an adjunct to PAP. The SURMOUNT-OSA trial explicitly included both groups, and the drug was effective in both.

The practical reality: CPAP remains the fastest, most reliable OSA treatment. It works the first night. Zepbound takes months of titration and produces its benefit indirectly through weight loss. But CPAP has adherence problems — an estimated 30–50% of patients don't tolerate it long-term. For that population, a second option matters.

Combination Use

Many sleep physicians are using Zepbound alongside CPAP rather than replacing it. As weight comes down and AHI improves, some patients can eventually transition off PAP therapy or to lower-pressure settings. This combined approach is consistent with the SURMOUNT-OSA Study 2 design.

The Insurance Angle

Here's where it gets interesting. Many commercial insurance plans exclude GLP-1 medications for weight loss. But insurers generally cover FDA-approved treatments for diagnosed sleep apnea — especially moderate-to-severe OSA, which is a billable medical condition with established coverage precedent (CPAP is covered for a reason).

For patients with an AHI ≥ 15 and obesity who have been denied Zepbound under a weight-loss framing, the OSA indication may unlock coverage that weight loss alone cannot. Formal sleep study documentation (in-lab polysomnography or home sleep apnea test) is typically required.

Medicare Part D

Medicare Part D plans are increasingly covering Zepbound for OSA, though coverage varies significantly by plan and by formulary placement. Some plans require documented CPAP trial and failure (or intolerance) before approving Zepbound. Others require ongoing CPAP use concurrent with the medication.

Who Qualifies

Based on the FDA label and SURMOUNT-OSA inclusion criteria:

• Adults ≥ 18 (not approved for pediatric OSA)
• BMI ≥ 30 (obesity)
• Moderate-to-severe OSA — meaning an AHI ≥ 15 events/hour, confirmed by sleep study
• Used alongside a reduced-calorie diet and increased physical activity

Patients who do not have obesity are not in the approved indication, even if they have severe OSA. Patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not use Zepbound.

Side Effects to Expect

The side effect profile is the same as Zepbound's weight-loss indication: nausea, diarrhea, vomiting, constipation, abdominal pain, injection site reactions, fatigue, burping, hair loss, and GERD. Warnings include pancreatitis, gallbladder problems, acute kidney injury, and (in type 2 diabetes patients) diabetic retinopathy.

Questions to Ask Your Sleep Physician

• Based on my sleep study, how much of my OSA is likely weight-related versus anatomical?
• Should I continue CPAP while starting Zepbound, or attempt a transition later?
• How will we monitor AHI changes during treatment — repeat sleep study, home testing?
• If my insurance covers Zepbound for OSA but not weight loss, does the prior authorization pathway differ?
• What's the plan if weight loss plateaus before OSA is resolved?